Synosis gains five early-stage CNS compounds from Roche
Roche has licensed CNS start-up Synosis Therapeutics rights to five of its neurological compounds for which it had previously discontinued development.
- Specialty Pharmaceuticals
- Includes Contract
- R&D and Marketing (Licensing)
- Reverse Licensing
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com